Glutamate theory in developing novel pharmacotherapies for obsessive compulsive disorder: Focusing on N-methyl-D-aspartate signaling

BioMedicine (Netherlands)

Volumn 2, Issue 2, 2012, Pages 75-79

  Wu, Po Lun ^a,b   Lane, Hsien Yuan ^a,b   Tang, Hwa Sheng ^c,d   Tsai, Guochuan E ^e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Glutamate; N methyl D aspartate; Obsessive compulsive disorder

Indexed keywords

CYCLOSERINE; GLUTAMIC ACID; GLYCINE; LAMOTRIGINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; PLACEBO; RILUZOLE; SARCOSINE; TOPIRAMATE;

ADD ON THERAPY; AMINO ACID ANALYSIS; BRAIN DEPTH STIMULATION; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL ANIMAL; FUNCTIONAL NEUROIMAGING; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GRIN2B GENE; HUMAN; LOW DRUG DOSE; NERVE CELL INHIBITION; NERVE CELL STIMULATION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PROTEIN FUNCTION; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SLC1A1 GENE;

ANIMALIA;

EID: 84862761642     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2012.04.003     Document Type: Review

References (67)

1. Koran L.M., Hanna G.L., Hollander E., Nestadt G., Simpson H.B. American Psychiatric Association. Practice Guidelines for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007, 164(Suppl. 7):5-53.
2. Jenike M.A. Clinical practice. Obsessive-compulsive disorder. N Engl J Med 2004, 350:259-265.
3. Stein D. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000, 47:296.
4. Denys D., van der Wee N., Janssen J., De Geus F. Westenberg HGM. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 2004, 55:1041-1045.
5. Westenberg H.G., Fineberg N.A., Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007, 2(Suppl. 3):14-27.
6. Ting J.T., Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive Disorder. Curr Chem Genomics 2008, 2:62-75.
7. Pittenger C., Bloch M.H., Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011, 132:314-332.
8. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005, 58:424-428.
9. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007, 17:761-767.
10. Pittenger C., Kelmendi B., Wasylink S., Bloch M.H., Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 2008, 28:363-367.
11. Van Ameringen M., Mancini C., Patterson B., Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006, 23:1-5.
12. Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 2010 Mar, 24:425-427.
13. Poyurovsky M., Glick I., Koran L. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2010, 24:861-866.
14. Denys D., de Geus F., van Megen H.J., Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004, 65:1040-1048.
15. Pasquini M., Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1173-1175.
16. Hezel D.M., Beattie K., Stewart S.E. Memantine as an Augmenting Agent for Severe Pediatric OCD. Am J Psychiatry 2009, 166:237.
17. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009, 29:51-55.
18. Thomson A.M., Walker V.E., Flynn D.M. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature 1989, 338:422-424.
19. Greenberg W.M., Benedict M.M., Doerfer J., Perrin M., Panek L., Cleveland W.L., et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res 2009 Mar, 43:664-670.
20. Walker D.L., Ressler K.J., Lu K., Davis M. Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of D-Cycloserine as Assessed with Fear-Potentiated Startle in Rats. J Neurosci 2002, 22:2343-2351.
21. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61:1136-1144.
22. Rothbaum B.O. Critical Parameters for D-Cycloserine Enhancement of Cognitive-Behaviorial Therapy for Obsessive-Compulsive Disorder. Am J Psychiatry 2008, 1(165):293-296.
23. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007, 62:835-838.
24. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of Behavior Therapy With D-Cycloserine for Obsessive-Compulsive Disorder. Am J Psychiatry 2008, 165:335-341.
25. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Yang M.C., et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007, 22:230-237.
26. Arnold P.D., Sicard T., Burroughs E., Richter M.A., Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006, 63:769-776.
27. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., Wu X., Fischer D.J., Van Etten-Lee M., et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006, 63:77-85.
28. Stewart S.E., Fagerness J.A., Platko J., Smoller J.W., Scharf J.M., Illmann C., et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1027-1033.
29. Wendland J.R., Moya P.R., Timpano K.R., Anavitarte A.P., Kruse M.R., Wheaton M.G., et al. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 2009, 66:408-416.
30. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004, 174:530-538.
31. Saxena S., Brody A.L., Schwartz J.M., Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998, Suppl. 35:26-37.
32. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995, 20:91-127.
33. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448:894-900.
34. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002, 99:13675-13680.
35. Otte D.M., Bilkei-Gorzo A., Filiou M.D., Turck C.W., Yilmaz O., Holst M.I., et al. Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 2009, 19:339-348.
36. Carlsson M.L. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000, 102:401-413.
37. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000, 39:1096-1103.
38. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004, 43:1146-1153.
39. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
40. Liu J., Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Ther 1995, 274:1209-1215.
41. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
42. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
43. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000, 57:270-276.
44. Moghaddam B. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 2003, 1003:131.
45. McGrath M.J., Campbell K.M., Parks C.R., Burton F.H. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000, 877:23-30.
46. Egashira N., Okuno R., Harada S., Matsushita M., Mishima K., Iwasaki K., et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008, 586:164-170.
47. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 1998, 95:15730-15734.
48. Chen L., Muhlhauser M., Yang C.R. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003, 89:691-703.
49. McBain C.J., Kleckner N.W., Wyrick S., Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol 1989, 36:556-565.
50. Wu P.L., Tang H.S., Lane H.Y., Tsai C.A., Tsai G.E. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol 2011, 31:369-374.
51. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004, 55:452-456.
52. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006, 60:645-649.
53. Lane H.Y., Lin C.H., Huang Y.J., Liao C.H., Chang Y.C., Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2009, 4:1-10.
54. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., et al. Molecular diversity of the NMDA receptor channel. Nature 1992, 358:36-41.
55. Watanabe M., Inoue Y., Sakimura K., Mishina M. Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol 1993, 338:377-390.
56. Mishina M., Mori H., Araki K., Kushiya E., Meguro H., Kutsuwada T., et al. Molecular and functional diversity of the NMDA receptor channel. Ann N Y Acad Sci 1993, 707:136-152.
57. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12:529-540.
58. Chapman D.E., Keefe K.A., Wilcox K.S. Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum. J Neurophysiol 2003, 89:69-80.
59. Buller A., Larson H., Schneider B., Beaton J., Morrisett R., Monaghan D. The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 1994, 14:5471-5484.
60. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003, 18(Suppl. 1):S23-S32.
61. Bergeron F., Otto A., Blache P., Day R., Denoroy L., Brandsch R., et al. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur J Biochem 1998, 257:556-561.
62. Saxena S., Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 2000, 23:563-586.
63. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997, 61:75-94.
64. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000, 31:302-312.
65. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
66. Pittaluga A., Raiteri L., Longordo F., Luccini E., Barbiero V.S., Racagni G., et al. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007, 53:27-36.
67. El Mansari M., Bouchard C., Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 1995, 13:117-127.